Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to crown any winners in the race for the next generation of anti-obesity ...

while Wegovy is a weekly injection. Do you need a prescription for Zepbound? Yes, you need a prescription for Zepbound. Prescriptions can typically be written by licensed healthcare professionals ...

Weight loss drugs like Ozempic and wegovy have become global sensation. In the recent years, companies like Novo Nordisk and Eli Lilly have GLP-1 agonists and dual GLP-1/GIP receptor agonists that ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...

While sales of both drugs have been rising on a sequential and yearly basis, the reported figures missed the consensus estimate of $4.3 billion for Mounjaro and $2.2 billion for Zepbound.

SAN FRANCISCO — When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens, it framed the move as a way ...